These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37145128)

  • 21. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
    Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
    Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance of genomic alterations between primary and recurrent breast cancer.
    Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
    Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
    Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
    Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated mutational landscape analysis of uterine leiomyosarcomas.
    Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
    Pipek O; Alpár D; Rusz O; Bödör C; Udvarnoki Z; Medgyes-Horváth A; Csabai I; Szállási Z; Madaras L; Kahán Z; Cserni G; Kővári B; Kulka J; Tőkés AM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
    Pareja F; Selenica P; Brown DN; Sebastiao APM; da Silva EM; Da Cruz Paula A; Del A; Fu L; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
    Histopathology; 2019 Jul; 75(1):139-145. PubMed ID: 30843622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
    Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
    Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
    Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
    Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
    Front Oncol; 2020; 10():1023. PubMed ID: 32695676
    [No Abstract]   [Full Text] [Related]  

  • 33. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
    Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer.
    Kaur P; Campo D; Porras TB; Ring A; Lu J; Chairez Y; Su Y; Kang I; Lang JE
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
    Wang S; Pitt JJ; Zheng Y; Yoshimatsu TF; Gao G; Sanni A; Oluwasola O; Ajani M; Fitzgerald D; Odetunde A; Khramtsova G; Hurley I; Popoola A; Falusi A; Ogundiran T; Obafunwa J; Ojengbede O; Ibrahim N; Barretina J; White KP; Huo D; Olopade OI
    Int J Cancer; 2019 Dec; 145(12):3321-3333. PubMed ID: 31173346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational landscape of inflammatory breast cancer.
    Bertucci F; Lerebours F; Ceccarelli M; Guille A; Syed N; Finetti P; Adélaïde J; Van Laere S; Goncalves A; Viens P; Birnbaum D; Mamessier E; Callens C; Bedognetti D
    J Transl Med; 2024 Apr; 22(1):374. PubMed ID: 38637846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
    Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
    J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
    Aftimos P; Oliveira M; Irrthum A; Fumagalli D; Sotiriou C; Gal-Yam EN; Robson ME; Ndozeng J; Di Leo A; Ciruelos EM; de Azambuja E; Viale G; Scheepers ED; Curigliano G; Bliss JM; Reis-Filho JS; Colleoni M; Balic M; Cardoso F; Albanell J; Duhem C; Marreaud S; Romagnoli D; Rojas B; Gombos A; Wildiers H; Guerrero-Zotano A; Hall P; Bonetti A; Larsson KF; Degiorgis M; Khodaverdi S; Greil R; Sverrisdóttir Á; Paoli M; Seyll E; Loibl S; Linderholm B; Zoppoli G; Davidson NE; Johannsson OT; Bedard PL; Loi S; Knox S; Cameron DA; Harbeck N; Montoya ML; Brandão M; Vingiani A; Caballero C; Hilbers FS; Yates LR; Benelli M; Venet D; Piccart MJ
    Cancer Discov; 2021 Nov; 11(11):2796-2811. PubMed ID: 34183353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
    Pitt JJ; Riester M; Zheng Y; Yoshimatsu TF; Sanni A; Oluwasola O; Veloso A; Labrot E; Wang S; Odetunde A; Ademola A; Okedere B; Mahan S; Leary R; Macomber M; Ajani M; Johnson RS; Fitzgerald D; Grundstad AJ; Tuteja JH; Khramtsova G; Zhang J; Sveen E; Hwang B; Clayton W; Nkwodimmah C; Famooto B; Obasi E; Aderoju V; Oludara M; Omodele F; Akinyele O; Adeoye A; Ogundiran T; Babalola C; MacIsaac K; Popoola A; Morrissey MP; Chen LS; Wang J; Olopade CO; Falusi AG; Winckler W; Haase K; Van Loo P; Obafunwa J; Papoutsakis D; Ojengbede O; Weber B; Ibrahim N; White KP; Huo D; Olopade OI; Barretina J
    Nat Commun; 2018 Oct; 9(1):4181. PubMed ID: 30327465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.